in this issue
Regions :: North America :: U.S.
Bayer enters into collaboration with Seattle Genetics for development of anticancer drugs
June 26, 2013 | Deepti Ramesh
Bayer says that its Bayer HealthCare subgroup has entered into a new antibody-drug conjugate (ADC) collaboration with biotechnology company Seattle Genetics (Bothell, WA). Bayer, under the deal, will get worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets. Under the terms of the agreement, Bayer will be responsible for research, product development, manufacturing, and commercialization of all products. In addition to an upfront payment and option exercise fees of up to $20 million...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee